Prothrombotic gene expression profile in vascular smooth muscle cells of human saphenous vein, but not internal mammary artery

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 4, 2008, Pages 705-710

  Payeli, S K ^a   Latini, R ^a   Gebhard, C ^a,b   Patrignani, A ^a   Wagner, U ^a   Luscher T F ^a,b   Tanner, F C ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Bypass graft disease; Coagulation; Migration; Tissue factor; Tissue plasminogen activator

Indexed keywords

BLOOD CLOTTING FACTOR 7A; PROTEINASE ACTIVATED RECEPTOR 2; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNAL MAMMARY ARTERY; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOLECULAR PROBE; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RECEPTOR BLOCKING; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; SUPERNATANT; THROMBOGENESIS; VASCULAR SMOOTH MUSCLE; ATHEROSCLEROSIS; AUTOTRANSPLANTATION; CORONARY ARTERY BYPASS GRAFT; CYTOLOGY; DNA MICROARRAY; GENETICS; GRAFT OCCLUSION; MAMMARY ARTERY; METABOLISM; THROMBOSIS; TISSUE DISTRIBUTION; TRANSPLANTATION;

ATHEROSCLEROSIS; BLOOD COAGULATION; CORONARY ARTERY BYPASS; GENE EXPRESSION PROFILING; GRAFT OCCLUSION, VASCULAR; HUMANS; LIPOPROTEINS; MAMMARY ARTERIES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; SAPHENOUS VEIN; THROMBOPLASTIN; THROMBOSIS; TISSUE DISTRIBUTION; TISSUE PLASMINOGEN ACTIVATOR; TRANSPLANTATION, AUTOLOGOUS;

EID: 42249090740     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.155333     Document Type: Article

References (33)

1. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LA, Gill CC, Taylor PC, Sheldon WC. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986;314:1-6.
2. Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal-thoracic-artery grafts-effects on survival over a 15-year period. N Engl J Med. 1996;334:216-219.
3. Goldman S, Zadina K, Krasnicka B, Moritz T, Sethi G, Copeland J, Ovitt T, Henderson W. Predictors of graft patency 3 years after coronary artery bypass graft surgery. Department of Veterans Affairs Cooperative Study Group No. 297. J Am Coll Cardiol. 1997;29:1563-1568.
4. Domanski MJ, Borkowf CB, Campeau L, Knatterud GL, White C, Hoogwerf B, Rosenberg Y, Geller NL. Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators. J Am Coll Cardiol. 2000;36:1877-1883.
5. Luscher TF, Turina MI, Braunwald E (ed). Coronary Artery Graft Disease. Springer Verlag; 1994.
6. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998;97:916-931.
7. Roubos N, Rosenfeldt FL, Richards SM, Conyers RA, Davis BB. Improved preservation of saphenous vein grafts by the use of glyceryl trinitrate-verapamil solution during harvesting. Circulation. 1995;92(Suppl):II31-II36.
8. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113:722-731.
9. Parolari A, Mussoni L, Frigerio M, Naliato M, Alamanni F, Polvani GL, Agrifoglio M, Veglia F, Tremoli E, Biglioli P, Camera M. The role of tissue factor and P-selectin in the procoagulant response that occurs in the first month after on-pump and off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2005;130:1561-1566.
10. Angles-Cano E, Balaton A, Le BB, Genot E, Elion J, Sultan Y. Production of monoclonal antibodies to the high fibrin-affinity, tissue-type plasminogen activator of human plasma. Demonstration of its endothelial origin by immunolocalization. Blood. 1985;66:913-920.
11. Yang Z, Ruschitzka F, Rabelink TJ, Noll G, Julmy F, Joch H, Gafner V, Aleksic I, Althaus U, Luscher TF. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels. Implications for venous bypass graft failure. Circulation. 1997;95:1870-1876.
12. Frischknecht K, Greutert H, Weisshaupt C, Kaspar M, Yang Z, Luscher TF, Carrel TP, Tanner FC. Different vascular smooth muscle cell apoptosis in the human internal mammary artery and the saphenous vein. Implications for bypass graft disease. J Vasc Res. 2006;43:338-346.
13. Ott I, Michaelis C, Schuermann M, Steppich B, Seitz I, Dewerchin M, Zohlnhofer D, Wessely R, Rudelius M, Schomig A, Carmeliet P. Vascular remodeling in mice lacking the cytoplasmic domain of tissue factor. Circ Res. 2005;97:293-298.
14. Weiss S, Frischknecht K, Greutert H, Payeli S, Steffel J, Luscher TF, Carrel TP, Tanner FC. Different Migration of Vascular Smooth Muscle Cells from Human Coronary Artery Bypass Vessels. Role of Rho/ROCK Pathway. J Vasc Res. 2007;44:149-156.
15. Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, Schulz U, Shojaati K, Matter CM, Yang Z, Luscher TF, Tanner FC. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation. 2006;114:1512-1521.
16. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004;24:1015-1022.
17. Parolari A, Colli S, Mussoni L, Eligini S, Naliato M, Wang X, Gandini S, Tremoli E, Biglioli P, Alamanni F. Coagulation and fibrinolytic markers in a two-month follow-up of coronary bypass surgery. J Thorac Cardiovasc Surg. 2003;125:336-343.
18. Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH Jr. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation. 1996;93:2014-2018.
19. Barstad RM, Ovrum E, Ringdal MA, Oystese R, Hamers MJ, Veiby OP, Rolfsen T, Stephens RW, Sakariassen KS. Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br J Haematol. 1996;94:517-525.
20. Steffel J, Akhmedov A, Greutert H, Luscher TF, Tanner FC. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation. 2005;112:341-349.
21. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002;277:32124-32132.
22. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 1999;99:1780-1787.
23. D'Andrea MR, Derian CK, Leturcq D, Baker SM, Brunmark A, Ling P, Darrow AL, Santulli RJ, Brass LF, Andrade-Gordon P. Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J Histochem Cytochem. 1998;46:157-164.
24. Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumiyoshi A, Asada Y. Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Res. 2002;107:271-276.
25. Cirillo P, Cali G, Golino P, Calabro P, Forte L, De RS, Pacileo M, Ragni M, Scopacasa F, Nitsch L, Chiariello M. Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation. 2004;109:2911-2916.
26. Ott I, Weigand B, Michl R, Seitz I, Sabbari-Erfani N, Neumann FJ, Schömig A. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation. 2005;111:349-355.
27. Siegbahn A, Johnell M, Nordin A, Aberg M, Velling T. TF/VIIa transactivate PDGFRbeta to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC. Arterioscler Thromb Vasc Biol. 2008;28:135-141.
28. Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA. 2001;286:442-429.
29. Carmeliet P, Stassen JM, Van V, I, Meidell RS, Collen D, Gerard RD. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood. 1997;90:1527-1534.
30. Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation. 1996;93:301-309.
31. Fay WP, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol. 2007;27:1231-1237.
32. Lijnen HR, Van HB, Lupu F, Moons L, Carmeliet P, Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol. 1998;18:1035-1045.
33. Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res. 1997;81:829-239.